Mr. Shaun Flanagan:

There are a number of immunotherapy drugs. Pembrolizumab, Nivolumab, Atezolizumab and Avelumab are all very similar drugs. Each has multiple uses, or "indications" as they are called in the wording of the European Medicines Agency. Pembrolizumab is reimbursed for a wide range of indications.

On the indication for ovarian or gynaecological cancers, to the best of my knowledge there is no European market authorisation for that yet. I am open to correction and will double-check, and as a consequence it would not be going through the process yet. When it gets a market authorisation in Europe for that -----